This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
Questions about our CME?
Questions about our CME?
Hang on a second…

This CME Activity has expired and is no longer available for credit.

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

IL-17 Inhibition: A Targeted Approach to the Management of Psoriatic Arthritis

IL-17 Inhibition: A Targeted Approach to the Management of Psoriatic Arthritis

Format

Webcast

Time to Complete

45 minutes

Released

October 7, 2016

Expires

January 7, 2018
Add to Queue


Maximum Credits

0.75 / AMA PRA Category 1 Credit(s)TM

Accredited Provider

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Commercial Supporter

Supported by an educational grant from Lilly USA, LLC.

Program Description

This interactive video discussion will provide you with the latest information on novel anti–IL-17 therapy with respect to:

  • Inhibition of key proinflammatory cytokines
  • Clinical efficacy of investigational IL-17A inhibitor agents
  • Advancing psoriatic arthritis management

Intended Audience

This program is intended for rheumatologists, dermatologists, internists, family physicians, and other healthcare professionals caring for patients with psoriatic arthritis.

Educational Objectives

Upon completion of this activity, participants should be able to:

  • Explain the role of IL-17A in the pathogenesis of PsA and the mechanism of action of biologics targeting IL-17A
  • Review new clinical trial data regarding the efficacies and safety profiles of biologics targeting IL-17A in the treatment of PsA and their expected role in clinical practice

Conflict Of Interest Disclosure Policy

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

Dafna D. Gladman, MD, FRCPC
Professor of Medicine
Division of Rheumatology
Department of Internal Medicine
University of Toronto
Rheumatologist
Division of Rheumatology
University Health Network
Toronto Western Hospital
Senior Scientist
Krembil Research Institute
Toronto, Canada

Dr. Gladman has disclosed that she has received consulting fees from Amgen, AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, and UCB.

Accredited Provider Disclosures

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Publishing Staff Disclosures

Ryan P. Topping, PhD, Megan K. Murphy, PhD, and Jenny Schulz, PhD, have nothing to disclose with regard to commercial interests.

Credit

0.75

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate.

Note: Your online certificate will be saved and accessible on the Clinical Care Options website and will not be saved to your myCME CME History.

If you have any questions relating to the accreditation of this activity, please contact ahughes@pimed.com.
Add to Queue